Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
NCT: NCT06496256 · RECRUITING
NCT IDNCT06496256
StatusRECRUITING
Start Date2024-10-31
Completion2028-12-31
SponsorPalette Life Sciences, Inc. (INDUSTRY)
First posted
Last updated
Brief Summary
Barrigel is intended to temporarily position the anterior rectal wall away from the prostate or prostate bed during radiotherapy treatment for prostate cancer and, in creating this space, it is the intent of Barrigel to reduce the radiation dose delivered to the anterior rectum.
Frequently Asked Questions
What is Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial?
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial is a clinical trial registered under NCT06496256. Current status: RECRUITING.
What is the status of NCT06496256?
The current status of NCT06496256 (Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial) is: RECRUITING.
When did Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial start?
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial started on 2024-10-31.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.